Trial · NCT06868381
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
NCT06868381, Phase 2, Not yet recruiting, Stanford University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of Baricitinib in Patients With Cardiac Sarcoidosis. Trials, record NCT06868381. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06868381
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
- NCT number
- NCT06868381
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Stanford University
- Conditions
- Cardiac Sarcoidosis
- Interventions
- Baricitinib (LY3009104) 4 mg
- First posted
- 2025-03-10
- Last updated
- 2026-02-10
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with resolution of cardiac FDG uptake on PET-CT | From baseline to end of treatment at 16 weeks | Resolution of FDG uptake will be determined by the consensus of two blinded nuclear medicine radiologists, in accordance with current SNMMI and ASNC guidelines |
| Secondary | Percent change in FDG avidity (SUVmax) in the cardiac lesion with greatest FDG avidity on PET-CT | From baseline to 8 weeks and end of treatment at 16 weeks | |
| Secondary | Percent change in total cardiac metabolic activity on FDG PET-CT | From baseline to 8 weeks and end of treatment at 16 weeks | Total cardiac metabolic activity is total lesion glycolysis within the heart |
| Secondary | Proportion of patients with resolution of extracardiac FDG uptake on PET-CT | From baseline to 8 weeks and end of treatment at 16 weeks | |
| Secondary | Percent change in FDG avidity (SUVmax) in up to six extracardiac lesions on PET-CT | From baseline to 8 weeks and end of treatment at 16 weeks | |
| Secondary | Percent change in total extracardiac metabolic activity on FDG PET-CT | From baseline to 8 weeks and end of treatment at 16 weeks | Total extracardiac metabolic activity is total lesion glycolysis of extracardiac disease |
| Secondary | Proportion of patients with resolution of cardiac FDG uptake on PET-CT | From baseline to 8 weeks and end of follow-up at 28 weeks | |
| Secondary | Change in sarcoidosis disease activity assessment | From baseline to 8 weeks and end of treatment at 16 weeks | Sarcoidosis disease activity assessed with King's Sarcoidosis Questionnaire. Total score range: 0 to 100, with 100 indicating the highest quality of life |
| Secondary | Change in fatigue assessment | From baseline to 8 weeks and end of treatment at 16 weeks | Fatigue assessed with FACIT-F. Total score range: 0-52, lower scores correspond with more fatigue |
| Secondary | Change from Baseline in Physician Disease Activity Visual Analogue Scale (VAS) | From baseline to 8 weeks and end of treatment at 16 weeks | Physician rates patient's disease on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06868381
GET https://conductscience.org/api/trials/v1/NCT06868381/registered